Monopar Therapeutics (MNPR) Free Cash Flow: 2017-2020
Historic Free Cash Flow for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to -$1.3 million.
- Monopar Therapeutics' Free Cash Flow fell 112.07% to -$1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.1 million, marking a year-over-year decrease of 42.61%. This contributed to the annual value of -$6.4 million for FY2024, which is 18.50% up from last year.
- Monopar Therapeutics' Free Cash Flow amounted to -$1.3 million in Q3 2020, which was down 30.64% from -$995,474 recorded in Q2 2020.
- Monopar Therapeutics' Free Cash Flow's 5-year high stood at -$305,128 during Q2 2017, with a 5-year trough of -$1.3 million in Q3 2020.
- For the 3-year period, Monopar Therapeutics' Free Cash Flow averaged around -$829,068, with its median value being -$752,863 (2018).
- Within the past 5 years, the most significant YoY rise in Monopar Therapeutics' Free Cash Flow was 49.82% (2018), while the steepest drop was 159.67% (2018).
- Monopar Therapeutics' Free Cash Flow (Quarterly) stood at -$816,021 in 2017, then skyrocketed by 36.37% to -$519,212 in 2018, then dropped by 28.79% to -$668,705 in 2019, then tumbled by 112.07% to -$1.3 million in 2020.
- Its Free Cash Flow was -$1.3 million in Q3 2020, compared to -$995,474 in Q2 2020 and -$1.1 million in Q1 2020.